Aligos Therapeutics Inc expected to post a loss of $2.16 a share - Earnings Preview

* Aligos Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024

* The South San Francisco California-based company is expected to report a 89.7% decrease in revenue to $333.33 thousand from $3.24 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Aligos Therapeutics Inc is for a loss of $2.16 per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Aligos Therapeutics Inc is $75.00​, above​ its last closing price of $8.87. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -4.00 -4.00 0.80 Beat 120

Jan. 1 2024 -4.75 -4.75 -5.50 Missed -15.8

Dec. 31 2023 -2.75 -6.75 -5.50 Beat 18.5​

Sep. 30 2023 -11.73 -11.87 -10.25 Beat 13.7

​​Jun. -12.19 -12.37 -10.75 Beat 13.1

30 2023

Mar. 31 2023 -11.93 -12.12 -13.25 Missed -9.3​

Dec. 31 2022 -11.45 -11.80 -12.75 Missed -8.1

Sep. 30 2022 -14.02 -14.50 -11.00 Beat 24.1

This summary was machine generated October 29 at 13:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)